Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-I7 plus Pembrolizumab in Refractory or Relapsed TNBC
NCT03752723Phase 2Completed
- Sponsor
- Genexine
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of efineptakin alfa in triple-negative breast cancer (TNBC) (2 arms), sponsored by Genexine. Primary endpoints: Incidence and nature of Dose Limiting Toxicities at 5 weeks, Incidence, nature and severity of adverse events at 24 months and 1 more. Started Mar 2019; status: completed.
02
Drugs
efineptakin alfa
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03752723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752723.